Adherence Analysis: Semaglutide QW Versus Other GLP-1 RAs As a result of the relatively short period of time from the launch of semaglutide QW to the index date, fewer patients receiving semaglutide QW were included in the adherence analysis at both 180 and 360 days ( n = 447 and n = 87, respectively), compared with patients receiving dulaglutide ( n = 17,073 and n = 7280, respectively) (Table 2), liraglutide ( n = 11,996 and n = 6137, respectively), and exenatide QW ( n = 5842 and n = 2683, respectively)
Is the carnivore diet healthy or just a meaty myth
As always, the most constructive approach is informed, personalized decision-making in conjunction with your healthcare provider(s)
A survey of GLP-1 users conducted by Morgan Stanley Research found that they reduce calorie intake meaningfully, with 50% reporting reductions of 20% or more
However, Wegovy is the only product currently approved to help with weight loss by the FDA